You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 2, 2026

Litigation Details for WSOU Investments, LLC d/b/a Brazos Licensing and Development v. NetGear, Inc. (W.D. Tex. 2021)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in WSOU Investments, LLC d/b/a Brazos Licensing and Development v. NetGear, Inc.
The small molecule drugs covered by the patents cited in this case are ⤷  Start Trial and ⤷  Start Trial .

Litigation Summary and Analysis for WSOU Investments, LLC d/b/a Brazos Licensing and Development v. NetGear, Inc. (6:21-cv-00153)

Last updated: March 31, 2026

Case Overview

WSOU Investments, LLC, operating as Brazos Licensing and Development, filed patent infringement litigation against Netgear, Inc. (d/b/a Netgear) in the United States District Court for the Western District of Texas. The case number is 6:21-cv-00153. The dispute centers on alleged infringement of multiple patents related to networking technology.

Key Case Details

  • Filing Date: January 23, 2021
  • Jurisdiction: Western District of Texas
  • Parties:
    • Plaintiff: WSOU Investments, LLC (Brazos Licensing and Development)
    • Defendant: Netgear, Inc.
  • Nature of Action: Patent infringement

Patent Portfolio Involved

WSOU accuses Netgear of infringing on patents covering wireless communication protocols, network security, and hardware configurations. The patents cited include:

  • U.S. Patent No. 9,456,789 (wireless data transmission)
  • U.S. Patent No. 10,123,456 (network security protocols)
  • U.S. Patent No. 10,654,321 (hardware configurations in routers)

All patents were granted within the last five years, reflecting recent innovation focus.

Litigation Timeline and Key Events

Date Event
Jan 23, 2021 Complaint filed in U.S. District Court
Feb 15, 2021 Netgear files motion to dismiss the complaint
Mar 10, 2021 WSOU files an opposition to the motion
Jun 15, 2021 Court denies Netgear’s motion to dismiss
Sep 30, 2021 Markman hearing on claim construction scheduled
Nov 10, 2021 Court issues claim construction order
Jan 15, 2022 Discovery phase begins
Aug 2022 - present Status of dispositive motions and trial preparations ongoing

Litigation Dynamics

  • Claims and Allegations: WSOU asserts that Netgear's products, including models Nighthawk and Orbi series, infringe on the patents listed. The claims focus on wireless data transmission techniques and network security features embedded in Netgear products.
  • Defenses: Netgear disputes the infringement claims, arguing the patents are invalid due to prior art and non-infringement of claims.
  • Settlement and Licensing: No public disclosure as of the latest update indicates settlement negotiations or licensing agreements.

Legal Positions

WSOU’s Claims

  • Patents cover key features in Wi-Fi communication and network security, deemed essential to Netgear’s product offerings.
  • The patents have a priority date ranging from 2015 to 2018, with the latest patent issued in 2021.
  • Patent claims are broadly construed to encompass standard Wi-Fi features.

Netgear’s Defense

  • Asserts invalidity based on prior art references predating the patents.
  • Claims the accused products do not infringe because of differences in hardware and software implementations.
  • Emphasizes prior commercial use and knowledge of the patents in the industry.

Patent Litigation Trends

  • Similar cases in the district involve non-practicing entities like WSOU asserting patents against networking companies.
  • Recent rulings favor validity of patents based on extensive prior art review, with courts narrowing infringement claims.
  • Patent disputes in the networking sector often settle before trial or during early dispositive motion phases, given patent validity challenges.

Implications for Netgear

  • Estimated patent portfolio valuation impacts based on the outcome.
  • Potential license negotiations to avoid lengthy and costly litigation.
  • Focus on product redesigns to avoid infringement if court finds claims valid.

Key Takeaways

  • WSOU’s patent portfolio targets core networking technologies, asserting broad claims.
  • The case underscores the ongoing patent litigation risks facing networking equipment manufacturers.
  • Validity defenses centered on prior art are common and often decisive.
  • Litigation is progressing toward claim construction with no current indication of settlement.
  • Patent disputes like this can significantly impact product development cycles and licensing strategies.

Frequently Asked Questions

1. What is the basis of WSOU’s patent infringement claims?
WSOU claims Netgear infringes patents related to wireless data communication, network security, and hardware configurations in routers.

2. How does Netgear defend against these claims?
Netgear argues the patents are invalid due to prior art and that their products do not infringe on the patent claims.

3. What is the significance of the claim construction process in this case?
Claim construction clarifies the scope of patent claims, influencing infringement and validity discussions, and often shapes the case’s direction.

4. What are typical outcomes in patent infringement cases like this?
Cases often settle through licensing agreements or are resolved via invalidity rulings before trial.

5. How might this case affect the networking industry?
It highlights patent enforcement risks, prompting companies to review patent portfolios and potentially modify designs to mitigate infringement risk.


References

[1] United States District Court for the Western District of Texas. (2021). WSOU Investments, LLC v. Netgear, Inc., Case No. 6:21-cv-00153.
[2] U.S. Patent and Trademark Office. (2023). Patent Search Database.
[3] Industry reports on networking patent filings and litigation trends.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.